Table 3.

Baseline Demographics of the Modified Intent-to-Treat Population

LevofloxacinCiprofloxacin
Males (n = 105)Females (n = 118)Males (n = 119)Females (n = 85)
Age (years)
    ≥6066 (62.9)69 (58.5)84 (70.6)48 (56.5)
    30–5933 (31.4)39 (33.1)32 (26.9)32 (37.6)
    <306 (5.7)10 (8.4)3 (2.5)5 (5.9)
Race
    White78 (74.3)92 (78)88 (74)76 (89.4)
    Black14 (13.3)11 (9.3)23 (19.3)2 (2.4)
    Asian2 (1.9)0 (0)0 (0)2 (2.4)
    Hispanic11 (10.5)14 (11.9)7 (5.9)5 (5.8)
    Other0 (0)1 (0.8)1 (0.8)0 (0)
Treatment setting
    Community101 (96.2)117 (99.2)116 (97.5)85 (100)
    Institutional4 (3.8)1 (0.8)3 (2.5)0 (0)
Catheter use
    Intermittent/Straight21 (20)12 (10.2)17 (14.3)8 (9.4)
    Chronic indwelling4 (3.8)0 (0)3 (2.5)2 (2.4)
Infection by most commonly occurring organisms
    Most common: Escherichia coli50 (47.6)75 (63.6)68 (57.1)59 (69.4)
    Second most commonEnterococcus faecalis: 13 (12.4)Klebsiella pneumoniae: 16 (13.6)E. faecalis: 12 (10)K. pneumoniae: 15 (17.6)
    Third most commonK. pneumoniae: 10 (9.5)Streptococcus agalactiae, Proteus mirabilis, E. faecalis (tie): 7 (6)K. pneumoniae: 10 (8.4)P. mirabilis: 3 (3.5)
Infected with >1 pathogen7 (6.7)4 (3.4)7 (5.9)3 (3.5)
  • Data are n (%).